EA201000383A1 - Способ ингибирования клостридиум диффициле введением оритаванцина - Google Patents
Способ ингибирования клостридиум диффициле введением оритаванцинаInfo
- Publication number
- EA201000383A1 EA201000383A1 EA201000383A EA201000383A EA201000383A1 EA 201000383 A1 EA201000383 A1 EA 201000383A1 EA 201000383 A EA201000383 A EA 201000383A EA 201000383 A EA201000383 A EA 201000383A EA 201000383 A1 EA201000383 A1 EA 201000383A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- clostridium difficile
- oritawan
- introduction
- inhibiting clostridium
- preventing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Pest Control & Pesticides (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Гликопептидные антибиотики, такие как оритаванцин, проявляют значительную активность и против вегетативной формы клостридиум диффициле, и против спор клостридиум диффициле. В изобретении описаны способы лечения, профилактики и предотвращения инфекций и заболеваний, вызванных клостридиум диффициле, у животных, включая людей.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97176607P | 2007-09-12 | 2007-09-12 | |
PCT/US2008/075949 WO2009036121A1 (en) | 2007-09-12 | 2008-09-11 | Method of inhibiting clostridium difficile by administration of oritavancin |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201000383A1 true EA201000383A1 (ru) | 2010-10-29 |
EA017564B1 EA017564B1 (ru) | 2013-01-30 |
Family
ID=40452464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201000383A EA017564B1 (ru) | 2007-09-12 | 2008-09-11 | Способ ингибирования клостридиум диффициле введением оритаванцина |
Country Status (10)
Country | Link |
---|---|
US (3) | US8518873B2 (ru) |
EP (1) | EP2195004B1 (ru) |
JP (1) | JP5591112B2 (ru) |
CN (1) | CN102316885A (ru) |
AU (1) | AU2008298987B2 (ru) |
BR (1) | BRPI0816662A2 (ru) |
CA (1) | CA2699550C (ru) |
EA (1) | EA017564B1 (ru) |
ES (1) | ES2535928T3 (ru) |
WO (1) | WO2009036121A1 (ru) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008298987B2 (en) * | 2007-09-12 | 2013-12-05 | Melinta Therapeutics, Inc. | Method of inhibiting clostridium difficile by administration of oritavancin |
WO2009126502A2 (en) * | 2008-04-08 | 2009-10-15 | Targanta Therapeutics Corp. | Methods of inhibiting and treating biofilms using glycopeptide antibiotics |
EP2424559B1 (en) * | 2009-04-28 | 2024-04-03 | Melinta Therapeutics, LLC | Methods of treating bacterial infections using oritavancin |
JP5986416B2 (ja) * | 2012-04-11 | 2016-09-06 | 花王株式会社 | 皮膚外用剤 |
US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
BR112015018625A2 (pt) | 2013-02-04 | 2017-09-19 | Seres Therapeutics Inc | composições e métodos |
EP3904502A3 (en) | 2013-02-04 | 2022-02-23 | Seres Therapeutics, Inc. | Compositions and methods |
AU2014232370B2 (en) | 2013-03-15 | 2018-11-01 | Seres Therapeutics, Inc. | Network-based microbial compositions and methods |
BR112016011830A2 (pt) | 2013-11-25 | 2017-09-26 | Seres Therapeutics Inc | composições bacterianas sinergísticas e métodos para produção e uso das mesmas. |
WO2015095241A2 (en) | 2013-12-16 | 2015-06-25 | Seres Health, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
US10191380B2 (en) * | 2014-10-14 | 2019-01-29 | Az Electronic Materials (Luxembourg) S.A.R.L. | Composition for resist patterning and method for forming pattern using same |
GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
BR112018016715A2 (pt) | 2016-02-18 | 2019-02-19 | Melinta Therapeutics, Inc. | ?formulações de oritavancina? |
CN107325159A (zh) * | 2016-04-29 | 2017-11-07 | 中国科学院上海药物研究所 | 一类万古霉素衍生物、其制备方法、药物组合物和用途 |
EA201892413A1 (ru) | 2016-05-09 | 2019-05-31 | Кселлия Фармасьютикалз Апс | Стабилизированные препараты гликопептидного антибиотика |
BR112020002992A2 (pt) | 2017-08-14 | 2020-08-18 | Seres Therapeutics, Inc. | composições e métodos para tratamento de doença colestática |
CA3109900A1 (en) * | 2018-08-17 | 2020-02-20 | Universidad Andres Bello | Method and pharmacological composition for the prevention of recurrent infections caused by clostridium difficile |
KR102444119B1 (ko) * | 2020-04-22 | 2022-09-16 | 주식회사 인트론바이오테크놀로지 | 클로스트리디오이데스 디피실리 균에 대하여 용균 활성을 갖는 항균단백질 cdl200 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2961184B2 (ja) * | 1990-05-07 | 1999-10-12 | ミヤリサン株式会社 | クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物 |
GB0212622D0 (en) * | 2002-05-31 | 2002-07-10 | Natural Technologies Group Ltd | Bacterial transforming agent |
US7317001B2 (en) * | 2002-06-06 | 2008-01-08 | Oscient Pharmaceuticals Corporation | Use of ramoplanin to treat diseases associated with the use of antibiotics |
DE60330161D1 (de) * | 2002-08-29 | 2009-12-31 | Activbiotics Pharma Llc | Rifalazil zur behandlung von infektionen mit clostridium difficile |
CN1918172B (zh) * | 2003-12-23 | 2011-09-14 | 活跃生物工艺学公司 | 利福霉素类似物及其用途 |
WO2007092582A2 (en) * | 2006-02-08 | 2007-08-16 | Biosynexus Incorporated | Neutralization of bacterial spores |
GB0714030D0 (en) * | 2007-07-18 | 2007-08-29 | Novacta Biosystems Ltd | The use of type-B lantibiotic-based compounds having antimicrobial activity |
AU2008298987B2 (en) * | 2007-09-12 | 2013-12-05 | Melinta Therapeutics, Inc. | Method of inhibiting clostridium difficile by administration of oritavancin |
-
2008
- 2008-09-11 AU AU2008298987A patent/AU2008298987B2/en active Active
- 2008-09-11 CA CA2699550A patent/CA2699550C/en active Active
- 2008-09-11 CN CN2008801102448A patent/CN102316885A/zh active Pending
- 2008-09-11 JP JP2010524973A patent/JP5591112B2/ja active Active
- 2008-09-11 ES ES08830916.6T patent/ES2535928T3/es active Active
- 2008-09-11 BR BRPI0816662A patent/BRPI0816662A2/pt not_active Application Discontinuation
- 2008-09-11 WO PCT/US2008/075949 patent/WO2009036121A1/en active Application Filing
- 2008-09-11 EP EP08830916.6A patent/EP2195004B1/en active Active
- 2008-09-11 US US12/676,420 patent/US8518873B2/en active Active
- 2008-09-11 EA EA201000383A patent/EA017564B1/ru unknown
-
2013
- 2013-07-24 US US13/950,202 patent/US8629100B2/en active Active
- 2013-12-10 US US14/101,645 patent/US9220749B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2010539179A (ja) | 2010-12-16 |
EA017564B1 (ru) | 2013-01-30 |
BRPI0816662A2 (pt) | 2017-06-13 |
US9220749B2 (en) | 2015-12-29 |
WO2009036121A1 (en) | 2009-03-19 |
CA2699550C (en) | 2020-08-18 |
US20140100157A1 (en) | 2014-04-10 |
ES2535928T3 (es) | 2015-05-19 |
EP2195004A4 (en) | 2011-12-28 |
US8629100B2 (en) | 2014-01-14 |
CN102316885A (zh) | 2012-01-11 |
AU2008298987B2 (en) | 2013-12-05 |
US20130310308A1 (en) | 2013-11-21 |
EP2195004B1 (en) | 2015-04-01 |
JP5591112B2 (ja) | 2014-09-17 |
CA2699550A1 (en) | 2009-03-19 |
AU2008298987A1 (en) | 2009-03-19 |
US8518873B2 (en) | 2013-08-27 |
US20100311646A1 (en) | 2010-12-09 |
EP2195004A1 (en) | 2010-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201000383A1 (ru) | Способ ингибирования клостридиум диффициле введением оритаванцина | |
PH12016502092A1 (en) | Antimicrobial compounds and methods of making and using the same | |
MY176900A (en) | Antimicrobial compounds and methods of making and using the same | |
MY173518A (en) | Antimicrobial compounds and methods of making and using the same | |
SG170813A1 (en) | New compounds | |
MX2009006536A (es) | Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales. | |
MY177564A (en) | Anti-nr10 antibody and use thereof | |
MX2009004047A (es) | Compuestos organicos. | |
EA201101477A1 (ru) | Органические соединения и их применение | |
PH12015502375A1 (en) | Antimicrobial compounds and methods of making and using the same | |
BRPI0712607A8 (pt) | métodos de tratamento de acidente vascular cerebral | |
TNSN08400A1 (en) | Organic compounds and their uses | |
WO2007109105A3 (en) | Flavivirus inhibition by sultams and related compounds | |
EA201100413A1 (ru) | Способ лечения бактериальной инфекции | |
MY165011A (en) | Antimicrobial compounds and methods of making and using the same | |
TW200716132A (en) | Novel chemical compounds | |
MY154715A (en) | Anti-nr10 antibody and use thereof | |
WO2005071067A3 (en) | Non-animal origin stabilizers and processes for producing the same | |
WO2008097364A3 (en) | Use of oritavancin for prevention and treatment of anthrax | |
DE602006012313D1 (de) | Kombination aus pyrimidylaminobenzamid-verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen | |
MX2021013281A (es) | Uso de molindona para el tratamiento de agresion. | |
TW200716579A (en) | Novel chemical compounds | |
WO2008033477A3 (en) | Antimicrobial activity in variants of lacritin | |
ATE533769T1 (de) | Als kinaseinhibitoren geeignete pyrrolotriazinverbindungen | |
WO2011103458A3 (en) | Compositions and methods for using and identifying antimicrobial agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC4A | Registration of transfer of a eurasian patent by assignment |